Vaxcyte, Inc. Files 8-K: Officer/Director Changes & Financials
Ticker: PCVX · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1649094
| Field | Detail |
|---|---|
| Company | Vaxcyte, Inc. (PCVX) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, financials
Related Tickers: PCVX
TL;DR
Vaxcyte 8-K: Leadership changes and financials filed Dec 19, 2025.
AI Summary
Vaxcyte, Inc. filed an 8-K on December 19, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits related to the period ending December 18, 2025.
Why It Matters
This 8-K filing indicates potential shifts in Vaxcyte's leadership and provides updated financial information, which could influence investor sentiment and strategic direction.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of corporate events and financial statements, not indicating any immediate operational or financial distress.
Key Numbers
- 20251218 — Reporting Period End Date (The filing covers events and financial information up to this date.)
- 20251219 — Filing Date (The date the 8-K was officially submitted to the SEC.)
Key Players & Entities
- Vaxcyte, Inc. (company) — Registrant
- SutroVax, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of Incorporation
FAQ
Who departed from Vaxcyte's board or officer positions?
The filing indicates the departure of directors or certain officers, but specific names are not detailed in the provided text.
Were new directors or officers elected/appointed?
Yes, the filing explicitly mentions the election of directors and the appointment of certain officers.
What is the primary business of Vaxcyte, Inc.?
Vaxcyte, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code 2836.
When was Vaxcyte, Inc. formerly known as?
Vaxcyte, Inc. was formerly known as SutroVax, Inc., with a name change date of July 24, 2015.
What specific items are covered under the 'Item Information' section of this 8-K?
The 'Item Information' covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'.
Filing Stats: 810 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2025-12-19 16:11:14
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PCVX The Nasdaq Sto
Filing Documents
- pcvx-20251218.htm (8-K) — 30KB
- exhibit101-formamendmentno.htm (EX-10.1) — 14KB
- 0001649094-25-000116.txt ( ) — 163KB
- pcvx-20251218.xsd (EX-101.SCH) — 2KB
- pcvx-20251218_lab.xml (EX-101.LAB) — 22KB
- pcvx-20251218_pre.xml (EX-101.PRE) — 13KB
- pcvx-20251218_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Form of Amendment to Executive Change in Control and Severance Agreements. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VAXCYTE, INC. Date: December 19, 2025 By: /s/ Andrew Guggenhime Andrew Guggenhime President and Chief Financial Officer